Quince Therapeutics, INC 8-K filings

Quince Therapeutics reported Q2 2026 results, highlighting the acquisition of Orphai Therapeutics, a $115 million private placement, and advancements in its LAM-001 program for pulmonary diseases.

Quince Therapeutics announces conditional resignations of CEO Dirk Thye and COO Brendan Hannah, with Brigette Roberts and John Militello conditionally appointed to lead.

Quince Therapeutics has completed the acquisition of Orphai Therapeutics, integrating Orphai's lead asset LAM-001, an inhaled rapamycin formulation, into its pipeline for treating serious pulmonary disorders.

Quince Therapeutics has finalized a 1-for-20 reverse stock split effective June 29, 2026, to consolidate its common shares.

Quince Therapeutics will implement a 1-for-20 reverse stock split effective June 29, 2026, to consolidate its outstanding common shares.

Quince Therapeutics shareholders approved a reverse stock split and the election of a director at the 2026 Annual Meeting.

Quince Therapeutics has successfully regained compliance with Nasdaq's minimum stockholders' equity listing requirement.

Quince Therapeutics announced positive Phase 2a data for LAM-001 in pulmonary hypertension, with a Phase 2b trial planned for mid-2026.

Quince Therapeutics has acquired Orphai Therapeutics, adding LAM-001 for pulmonary diseases and raising $115 million in upfront financing.

Quince Therapeutics announced it has regained compliance with Nasdaq's minimum bid price requirement, though it still needs to address market value of listed securities.

Quince Therapeutics has expanded its Board of Directors to four members with the appointment of independent director June Bray.

Quince Therapeutics, Inc. has officially filed a Certificate of Amendment to enact a 1-for-10 reverse stock split, effective April 10, 2026, with trading on a split-adjusted basis commencing April 13, 2026.

Quince Therapeutics eliminated approximately $16.4 million of EIB debt for a $5.5 million payment, advancing its restructuring and strategic alternatives review.

Quince Therapeutics, Inc. received notices from Nasdaq regarding non-compliance with minimum bid price and market value of listed securities requirements, risking potential delisting.

Quince Therapeutics is exploring strategic alternatives, including a reverse merger, after its lead drug candidate, eDSP, failed to meet endpoints in a clinical trial.

Five directors, including Rajiv Patni and Luca Benatti, have resigned from Quince Therapeutics' Board, effective January 30, 2026.

Quince Therapeutics announced its lead asset, eDSP, failed to meet primary and key secondary endpoints in its pivotal Phase 3 NEAT clinical trial for Ataxia-Telangiectasia, leading to cessation of development.

Quince Therapeutics reported third-quarter 2025 financial results and provided an update on its pivotal Phase 3 NEAT clinical trial for eDSP, which remains on track for topline results in Q1 2026.

Quince Therapeutics issued an 8-K to retract a statement made during its Virtual Investor Day regarding the efficacy of N-acetyl-L-leucine (NALL) in ataxia-telangiectasia.

Quince Therapeutics has amended its European Investment Bank credit facility, reducing its minimum cash balance requirement and modifying interest payment terms for early 2026.

Quince Therapeutics announced its second quarter 2025 financial results and key business updates, including the completion of enrollment for its pivotal Phase 3 NEAT clinical trial.

Quince Therapeutics, Inc. announced the completion of patient enrollment in its pivotal Phase 3 NEAT clinical trial for eDSP, a potential first-to-market treatment for the rare neurodegenerative disease Ataxia-Telangiectasia.

Quince Therapeutics, Inc. has announced a private placement raising approximately $11.5 million through the sale of common stock, pre-funded warrants, and common warrants to institutional investors and company management.

Quince Therapeutics, Inc. announced that its stockholders approved all key proposals at the Annual Meeting, including the election of three Class III directors, an increase in authorized common stock, and a potential one-for-ten reverse stock split.

Quince Therapeutics is considering concluding enrollment early for its Phase 3 NEAT clinical trial in Ataxia-Telangiectasia (A-T) to align topline results with its existing cash runway.

Quince Therapeutics announces its fiscal year 2024 financial results, highlighting progress in its Phase 3 NEAT clinical trial and an expected cash runway into 2026.

Quince Therapeutics has successfully regained compliance with Nasdaq's minimum bid price requirement after its stock price closed above $1.00 for ten consecutive trading days.

Quince Therapeutics announced encouraging enrollment progress in its Phase 3 NEAT trial for Ataxia-Telangiectasia and reported its third quarter 2024 financial results.

Quince Therapeutics announced its Q2 2024 financial results, highlighted the first patient enrollment in its Phase 3 NEAT trial for Ataxia-Telangiectasia (A-T), and provided a business update.

Quince Therapeutics has received a notice from Nasdaq for failing to maintain the minimum bid price of $1.00 per share for 34 consecutive trading days, putting its listing at risk.